Capricor Therapeutics
The Senior Director, Quality Assurance & Quality Systems at Capricor Therapeutics leads the company's quality strategies and systems, overseeing compliance, inspection readiness, and quality oversight across development, manufacturing, and commercialization phases of cell and exosome-based therapies. The role involves collaborating with cross-functional teams to support regulatory submissions, clinical trials, and product launches, with a focus on continuous improvement and fostering a quality-focused culture.
Headquarters
San Diego, California, United States
Company Size
51-200 employees
Founded
2005
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a San Diego–based biotechnology company developing cell- and exosome-based therapeutics for muscular and other select diseases. Its lead candidate, deramiocel (CAP‑1002), is an allogeneic cell therapy currently in Phase 3 clinical development for Duchenne muscular dystrophy. Capricor is also advancing exosome technology as a next‑generation platform, engineering exosomes to deliver nucleic acids and proteins to treat or prevent a variety of diseases. The company focuses on translating these platforms into novel therapeutic and preventive products.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Capricor Therapeutics.
Duchenne trial drug from Capricor slows key task decline 83%
23 hours ago
Executive Director, GMP Quality Assurance
Artiva Biotherapeutics
VP/SVP, Head of Quality
TScan Therapeutics
Principal, Quality Assurance
Lyell Immunopharma
Manager, Quality Assurance
8a7883c6700909c4017010d9b3290690
Senior Manager, Quality Assurance
Vera Therapeutics, Inc.
Manufacturing Quality Specialist
Artiva Biotherapeutics